[7] However, the Swedish manufacturer abruptly[citation needed] withdrew distribution of this drug in Europe in March 2020 for commercial reasons.

Auxilium's submission of a License Application to the FDA for Xiaflex for the potential treatment of Peyronie's disease, an excess of inelastic collagen causing penile curvature deformity.

[10] Auxilium has also reported additional trials for potential use of Xiaflex are underway for the treatment of frozen shoulder, cellulite reductions and both human and canine lipomas.

[11] The most common side effects include lymphadenopathy (swollen lymph nodes), itching, pain, oedema, and bleeding (for example in the form of bruises or ecchymoses).

[13] The enzymes do not reach the bloodstream in significant amounts and are presumed to largely stay at the point of injection[12] until they are broken down by proteases.

It is theorised that drugs interfering with matrix metalloproteinases, such as tetracyclines, anthracyclines, quinolones and anthraquinone derivatives, could reduce the efficacy of the collagenases, but no clinical evidence for such an interaction has been observed.